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Research News
In preclinical models of cancer, gene
therapy with interleukin 12 (IL-12) has
reached unprecedented levels of success
when combined with immunotherapy
approaches such as gene transfer of other
cytokines and/or chemokines,
costimulatory molecules or adoptive cell
therapy. These combinations have been
found to produce synergistic rather than
additive effects. Meanwhile, IL-12 gene
therapy is beginning clinical testing as a
single agent, but combination strategies
are at hand.
Since the discovery of interleukin 12
(IL-12), studies have tried to ascertain its
efficacy as an anticancer agent1. Indeed,
recombinant IL-12 given systemically had
powerful antitumor activities in murine
models that led to its clinical
development, which began in 1994.
Interferon γ (IFN-γ) was identified as the
key downstream factor induced by IL-12
that is known to be necessary for the
antitumor effects. In Phase I clinical trials
designed in an intrapatient dose
escalation fashion, it was not realized that
initial low doses of IL-12 resulted in
desensitization against the biological
effects of IFN-γproduced upon
subsequent IL-12 doses. Intravenous (i.v.)
doses, which were tolerated in Phase I,
caused severe toxicity in Phase II clinical
trials and thus put a stop to the clinical
development of this active antitumoral
agent for several years.
Cancer gene therapy with IL-12
When considering a protein with
antitumor activity but serious systemic
potential toxicity, the concept of local gene
therapy comes to mind. Several groups
realized simultaneously that in vivo gene
transduction of malignant cells with IL-12
genes could be therapeutically useful, and
would avoid toxicity by confining the
potentially damaging agent to the tumor
milieu. In fact, intense effects in mice were
reported when using direct intratumor
injection of defective recombinant
adenoviruses encoding IL-12 and these
vectors are still the most powerful at
achieving tumor cell gene transfer
in vivo2.
All the available data have been
generated with transplantable cell lines
that represent various carcinomas,
sarcomas, melanomas and lymphomas
but not with spontaneously arising
tumors. Generally, IL-12 gene transfer
leads to significant antitumor activity in
these experimental studies and complete
eradications are often reported, but there
is still room for improvement. Moreover,
efficacy on naturally occurring
malignancies could be less than in
transplanted tumors.
Several mechanisms of antitumor
activity have been identified and each
contributed differently to the overall
therapeutic outcome in each given tumor
model. On the one hand, IL-12 promotes a
potent cellular immune response in
which tumor-specific cytotoxic T
lymphocytes (CTLs) and T helper (Th)
cells secrete Th1 cytokines. However,
CD4+ Th cells are necessary for the
therapeutic activity only in some models
and they seem suppressive in some
instances. On the other hand, absence of
CD8+ T cells severely impairs the
antitumor effects in most models.
Natural killer (NK)-cell depletion
demonstrated a clear role for this
lymphoid population in precisely those
tumors considered less immunogenic.
IL-12 nonimmune mechanisms have
been identified and the most prominent is
the ability of IL-12 to downregulate the
formation of new vessels into growing
tumors3, also confirmed with gene
transfer of IL-12 (Ref. 4). IL-12 receptors
have not been found on endothelial cells
and angiogenesis is turned off by
secondary mediators of the IL-12–IFN-γ
pathway, in which the CXC chemokines
IFN-γ-inducible protein 10 (IP-10) and
monokine induced by IFN-γ(Mig) have
been shown to play a crucial role3. In
addition, this cytokine cascade induces
homing receptors on endothelium for the
infiltration of lymphocytes into the
malignant tissue (G. Mazzolini et al.,
unpublished).
Cytokines and chemokines that show
synergy with IL-12 gene transfer
Based on previous data with purified
proteins, F.L. Graham and colleagues
pioneered the combination of two
adenoviruses, one encoding IL-2 and the
other IL-12, which were coinjected into
tumor nodules. As a result of synergistic
effects, they observed >60% complete
regression of established mammary
carcinomas and induction of potent
antitumor CTL activity5. Recent data
show that the closely related cytokine
IL-15 synergizes with IL-12, as seen with
stable double-transfected human lung
cancer cells xenografted in nude mice6.
The antitumor mechanisms studied in
this artificial system are independent of T,
B and NK cells but unravel the intriguing
involvement of neutrophils in the
rejections.
IL-18 has been identified as a potent
inducer of IFN-γ. Importantly, IL-18
upregulates the expression of IL-12
receptors. In a reported poorly
immunogenic tumor (MCA205), a clear
synergy was observed in the antitumor
effects mainly mediated by NK cells in this
case7. However, the administration of
recombinant proteins has a threatening
synergistic effect in that it induces lethal
levels of IFN-γ.
Genes encoding lymphocyte attracting
chemokines can be successfully combined
with IL-12. This approach has shown
remarkable efficacy with adenoviruses
encoding the chemokines lymphotactin8
and IP-10 (Ref. 9). The lymphotactin gene
and both IL-12 genes were engineered in
the same construct, but further research is
needed to address whether a single viral
vector or a combination of two vectors is
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better. Lymphotactin by itself induced
lymphoid infiltration but it was clinically
meaningless because mammary
carcinomas progressed8. In addition, IP-10
transduced by adenovirus into
experimental colon carcinomas had little
antitumor effect but caused necrosis
consistent with its antiangiogenic
properties. Combination therapy with
IP-10 and IL-12 showed great potency in a
scenario where CD4+ T cells, CD8+ T cells
and NK cells were showing prominent
roles. Reducing the dose of the IL-12
adenovirus by one order of magnitude
eradicated the tumors when combined
with IP-10, thus reducing potential
toxicity. Interestingly, colocalization of
both adenoviruses in the same tumor
nodule was required for the systemic
antitumor effect, which was not seen if
given separately to two distantly
implanted malignant nodules9. Other
combinations are being tested, some
involving three players. One important
issue is to identify a setting for comparison




Apart from soluble mediators, certain
membrane-bound proteins are required to
ignite and sustain the immune response.
Such molecules are typically restricted to
the surface of professional antigen-
presenting cells and can be transfected to
tumors in an attempt to make them more
immunogenic.
B7 molecules are a family of proteins
that interact with counter-receptors on
T cells and provide signals that modulate
the immune response. Transfection of
B7-1 (CD80) and B7-2 (CD86) makes
tumor cells more immunogenic and
combination with IL-12 has been proved
beneficial in certain models10, but not in
others11.
The 4-1BB ligand is a tumor necrosis
factor (TNF) family member expressed on
the membrane of mature dendritic cells
and other cell types that upon
transfection enhances the
immunogenicity of tumors. This molecule
interacts with 4-1BB, a surface
differentiation antigen restricted to
activated T cells and NK cells. Intratumor
injections with adenovirus encoding
4-1BB ligand and IL-12 mutually
potentiate their effect against large and
well-established liver metastasis of an
NK-sensitive colon cancer12. In addition,
tumor immunity can be triggered by
agonistic monoclonal antibodies (mAbs)
acting on 4-1BB. Regimes of intratumor
gene transfer of IL-12 and anti-4-1BB
mAbs show synergizing properties13 that
are more potent than those observed with
the natural ligand. This is explained
because antibodies show wide-reaching
distribution and stimulate every
available 4-1BB+ lymphocyte, in contrast
to the membrane bound 4-1BB natural
ligand.
Adoptive cell therapy strategies that
synergize with IL-12 gene transfer
IL-12 induces CTL expansion, which
facilitates the culture of effector cells for
adoptive cell therapy regimes.
Surprisingly, IL-12 synergy with adoptive
T-cell therapy not only provides CTLs, but
also operates at the effector level. These
phenomena were unveiled by studies of
mice with systemic tumor disease, in
which some malignant nodules were
adenovirally transduced with IL-12 and
subsequently given antitumor CTLs i.v.
(Ref. 14). Later experimentation has
shown a key role for inflammatory
adhesion molecules that are induced on
the endothelium of peritumoral capillaries
by IL-12 gene transfer (G. Mazzolini et al.,
unpublished).
IL-12 can be used to upregulate
artificially the functions of dendritic cells
to promote cellular immune responses.
Two studies have concluded that
intratumor injection of dendritic cells
engineered to secrete IL-12, by means of
adenoviral15 or retroviral transfection16,
eradicates established tumors derived
from at least five different tumor cell lines.
IL-12 transfection into dendritic cells is
probably acting at a series of levels,
stimulating T cells, NK cells and dendritic
cells in an autocrine fashion. Dendritic
cells capture tumor antigens inside the
malignant tissue and migrate avidly to
draining lymph nodes where antigens are
presented while high local levels of IL-12
are being produced.
Conclusion
We propose a general mechanism of action
for these synergistic combinations in
which a halt in tumor growth by
angiogenesis inhibition and NK activation
trailblaze the route for artificially boosted
T-cell responses (Fig. 1). Gene transfer of
IL-12 into tumors is now entering clinical
testing and it is hoped that the safety
records will be as good as the preclinical
data. Combination of the complementary
immunotherapy approaches described
above is the obvious next step to increase




























Fig. 1. Mechanisms involved in the antitumoral effects of interleukin (IL)-12 that can be potentiated in combination
immunotherapy regimes as indicated in the colored boxes. IL-12 is secreted locally by transfected malignant cells and
it triggers IFN-γproduction from different cellular sources. As a result, immune and nonimmune therapeutic
mechanisms are turned on. The combination of IL-12 with other immunostimulating genes or adoptive T-cell therapy
has been observed to enhance efficacy in a synergistic fashion. Abbreviations: DC, dendritic cell; IFN-γ, interferon γ;
IL-12, interleukin 12; IP-10, IFN-γ-inducible protein 10; Ltn, lymphotactin; Mig, monokine induced by IFN-γ; Mφ,
macrophage; NK, natural killer.
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Is TGF-β1 the key to suppression of human asthma?
Atsuhito Nakao
Transforming growth factor β1 (TGF-β1) is
produced by many types of cells that are
activated in the asthmatic response. Recent
studies have highlighted this cytokine as an
important negative regulator in an
experimental model of asthma. Although
the role of TGF-β1 in human asthma
remains obscure, data derived from animal
models have encouraged the further
investigation of such suppression
mechanisms in order to develop novel
therapies for asthma.
Asthma is a complex disorder
characterized by airway hyper-
responsiveness (AHR) and airway
inflammation. Evidence has accumulated
regarding factors that promote the
asthma phenotype1, but the mechanisms
by which the asthma phenotype is
suppressed are largely unclear. Recently,
a pleiotropic cytokine, transforming
growth factor β1 (TGF-β1), has been
reported to function as a negative
regulator of AHR and airway
inflammation in an experimental model of
asthma2–5. Here, we consider this evidence
and discuss possible roles of TGF-β1 in
suppression of human asthma.
Current understanding of the
pathophysiology of asthma
Asthma is a complex disorder consisting of
various cellular and/or
cytokine/chemokine networks1. The
presentation of inhaled allergens to CD4+
T cells in the lungs of susceptible
individuals results in the production of
cytokines such as interleukin 4 (IL-4),
IL-5, IL-9 and IL-13, which orchestrate
the differentiation, recruitment and
activation of eosinophils and mast cells in
the airway mucosa1,6,7. Such effector cells
release inflammatory mediators that
cause acute bronchial constriction,
disruption of the airway epithelial layer,
alterations in neural control of airway
tone, increased mucus production and
increased smooth muscle mass. These
consequences of the inflammatory process
induce AHR. Recent studies have shown
that not only T cells but also a variety of
other cells, including mast cells, bronchial
epithelial cells and smooth muscle cells,
which are activated by various mediators,
contribute to the development of AHR in
part through the secretion of cytokines or
chemokines that generate tissue
inflammation8,9.
How does TGF-β elicit its biological effects?
TGF-β1 is a member of the TGF-β
superfamily, which comprises a large
number of cytokines including TGF-βs,
bone morphogenetic proteins (BMPs) and
activins. These cytokines carry out a wide
range of biological functions including cell
proliferation, differentiation and
apoptosis.
TGF-β1 is inhibitory for inflammatory
cells such as T cells, B cells, dendritic cells,
mast cells and eosinophils, and also
modifies the functions of structural cells
such as bronchial epithelial cells,
fibroblasts and bronchial smooth muscle
